Theresa J. Goletz

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

E.Y. Woo, Christina Chu, Theresa J. Goletz et al. · PubMed · 2001 · 1.1K citations

Life Sciences, Immunology, Oncology +17

gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

Willem W. Overwijk, Allan Tsung, Kari R. Irvine et al. · The Journal of Experimental Medicine · 1998 · 493 citations · Full text

Life Sciences, Immunology, Oncology +17

Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses

Marisa K. Joubert, Martha Hokom, Catherine M. Eakin et al. · Journal of Biological Chemistry · 2012 · 265 citations · Full text

Life Sciences, Immunology, Molecular Pharmaceutics +16

Pilot trial of tumor‐specific peptide vaccination and continuous infusion interleukin‐2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter‐institute NIH study†

Ramzi Dagher, Lauren Long, Elizabeth J. Read et al. · Medical and Pediatric Oncology · 2002 · 150 citations

Medicine, Immunology, Oncology +17

Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine

Vincenzo Bronte, Miles W. Carroll, Theresa J. Goletz et al. · Proceedings of the National Academy of Sciences · 1997 · 141 citations

Life Sciences, Cancer Biology, Immunology +16